Multivariate analysis of patients with MPNs receiving antiplatelet or anticoagulation therapy revealed an increase in risk of bleeding events in these patients.
Researchers sought to determine the risk for patients with MPNs to develop thromboembolisms, which may be associated with cell death related to a process called neutrophil extracellular trap formation.
As myeloproliferative neoplasms (MPN) are a particularly rare form of blood cancer without a clear cause, it may be difficult to understand how lifestyle factors can affect both MPN risk and symptom burden. What has research suggested about the ways certain lifestyle factors affect MPNs?
Investigators assessed studies for evidence to guide the management of MPN in patients with COVID-19.
Researchers sought to determine the role of BRCA1/2 mutations in patients with MPNs.
Researchers sought to determine the prognostic role of cytogenetics in Philadelphia-negative myeloproliferative neoplasms.
As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?
Researchers found a high incidence of thromboembolic events in young patients with myeloproliferative neoplasms, especially polycythemia vera.
Researchers sought to determine the occurrence of thrombotic events in a cohort of pediatric patients with myeloproliferative neoplasms.
Review highlights current approaches to risk stratification, differential diagnosis, and the optimal use of current treatment options for polycythemia vera.
